CD4 and angioimmunoblastic T-cell lymphoma: Thus, using anti-CD4-CAR T cells in AITL patients as used in this study, might represent a promising strategy, even though healthy CD4 T cells will also be depleted and on the long term this approach can result in CD4 T cell elimination and immunosuppression.